CD38 and Miyoshi myopathy: The HSPC pool distribution after MM-EV treatment was analyzed according to the classical differentiation model (Figure 3A) where it is possible to define two HSPC populations: stem/early progenitors (CD34+CD45RA−−/+CD38−−) and late progenitors (CD34+CD45RA−−/+CD38+; Figure 3A) (30, 31).